Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heidi Harvie

Urogynecology and Reconstructive Pelvic Surgery Philadelphia, PA Medical Doctor

NPI 1740346725 CMS profile 123840

3400 Spruce Street, 1 West Gates, Philadelphia, PA 19104

Open in the dashboard

General payments

$2,966

7 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heidi Harvie of Philadelphia, PA is reported in the CMS Open Payments database as having received $2,966 across 7 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,834 1
2023 General $14 1
2022 General $51 2
2020 General $33 2
2019 General $34 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heidi Harvie
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Heidi Harvie were reported at $2,834. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Heidi Harvie Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $34 $358 $132–$1,270 $163
2020 $33 $198 $86–$642 $114
2021 $0 $361 $118–$1,182 $132
2022 $51 $410 $128–$1,175 $149
2023 $14 $434 $152–$1,344 $160
2024 $0 $494 $193–$1,331 $164
2025 $2,834 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,834 1 payment
  2. Caldera Medical, Inc $51 2 payments
  3. CooperSurgical, Inc. $34 1 payment
  4. Baxter Healthcare $19 1 payment
  5. Astellas Pharma US Inc $15 1 payment
  6. Boston Scientific Corporation $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $2,834 1 payment
  2. Food and Beverage $81 4 payments
  3. Gift $51 2 payments
Products named General payments · program years 2019–2025
  1. Desara $51 2 payments
  2. Endosee $34 1 payment
  3. FLOSEAL $19 1 payment
  4. MYRBETRIQ $15 1 payment
  5. Solyx SIS System $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

608

Median for Obstetrics & Gynecology: 65

Drug cost

$145,736

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

44.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 96 $63,805
Gemtesa Vibegron Brand 83 $58,090
Estradiol Generic 232 $13,604
Premarin Estrogens, Conjugated Brand 11 $4,679
Methenamine Hippurate Generic 52 $4,065
Yuvafem Estradiol Brand 13 $906
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 56 $387
Cephalexin Generic 23 $78
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 14 $74
Ciprofloxacin Hcl Generic 28 $48

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$72,214

Medicare's payments for the services billed

Medicare patients

182

Average age 73

Services billed

522

182 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 54%
Osteoporosis 31%
Depression 23%
Diabetes 19%
Cancer 19%
Ischemic heart disease 17%
Chronic kidney disease 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record